Skip to main content

Table 2 Clinical data of PAH group

From: Loss of alveolar membrane diffusing capacity and pulmonary capillary blood volume in pulmonary arterial hypertension

Etiology of PAH n(%)  
Idiopathic 21(75%)
Heritable 3(10.7%)
Drug and toxin-induced 1(3.6%)
Associated with 3(10.7%)
NYHA class n(%)  
I 4(14%)
II 14(50%)
III 10(36%)
IV 0(0%)
Medications n(%)  
Prostacyclin 6(21.4%)
PDE5i 4(14.3%)
ERA 4(14.3%)
Prostacyclin + PDE5i 4(14.3%)
Prsoatcyclin + ERA 2(7.15%)
ERA + PDE5i 2(7.15%)
Prostacyclin + PDE5i + ERA 6(21.4%)
6-MWD (m) 487±24
Right ventricular systolic pressure (mmHg) 78 ±5
Mean pulmonary arterial pressure (mmHg) 52±3
Mean pulmonary capillary wedge pressure (mmHg) 13±1
Cardiac output (L/min) 6±0.4
Cardiac index (L/min/m2) 3±0.2
Pulmonary vascular resistance (wood units) 7.8±0.9
  1. PAH: pulmonary arterial hypertension.
  2. NYHA: new york heart association.
  3. PDE5i: phosphodiesterase type 5 inhibitor.
  4. ERA: endothelin receptor antagonist.
  5. 6-MWD: 6 minute walk distance.